While it’s a popular tactic among a certain strand of financial influencers – those keen to hawk trading courses – to present the stock market as a space for the rapid accumulation of wealth, the truth is a much more boring, but nevertheless effective story about investing in promising companies and patiently waiting as they prove their value over five, ten or even twenty years.
This article is disseminated in partnership with small-cap stocks SBC Medical Group Holdings Inc. and Delta Gold Technologies PLC. It is intended to inform investors and should not be taken as a recommendation or financial advice.
This is why it’s so dangerous to “take a flyer” and invest in a company you barely know, choosing the thrill of a gamble, instead of holding yourself to a higher standard, where theses are always as ironclad as could reasonably be expected, ensuring that you can sleep well at night and get on with your life. Green flags to look out for in this regard include:
- Employees behind the companies in your portfolio working in your best interests, through insider ownership, strong governance, or ideally both.
- Operations in markets propelled by long-term tailwinds.
- Products and services that make strong cases for adding value to the client experience.
In my unending quest to populate your watchlist with worthwhile candidates, in the latest edition of Stockhouse’s Weekly Market Movers, I’ll highlight two small-cap stocks whose underlying companies are in it for the long haul and back up their request for you to tag along for the ride with ample evidence of operational strength.
SBC Medical Group Holdings
First in our pair of small-cap stocks combining strong fundamentals with a long-term growth runway is SBC Medical Group, market cap US$329 million, tracking a healthcare management support company operating primarily in Japan and the United States across a variety of fields, including cosmetic treatments, dermatology, orthopedics, fertility, gynecology, dentistry, alopecia and ophthalmology, guided by a shared mission to “contribute to the well-being of people around the world through medical innovation.”
The company, founded in 2000 in Fujisawa, Japan, has since grown into the country’s largest aesthetic medical group, while actively expanding into the US and Southeast Asia, closing out 2025 with 283 operating clinics and 6.63 million patients served throughout the year.
SBC’s customer base has grown exponentially since 2010, as per slide 17 of the Q4 2025 investor deck, supported by what the company refers to as its Structural Competitive Advantage Model (slide 9), where integrated infrastructure, HR best practices, state-of-the-art data analysis and continuing medical education are designed to combine into increasing brand trust.
This comprehensive approach to doing business, paired with an efficient development model, where new clinics turn profitable in only five months after an initial investment of only US$486,000, has allowed SBC to post solid financial results since going public in September 2024. Here’s how the company’s 2025 shaped up:
- Revenue of US$174 million, down by 15 per cent year-over-year, reflecting a 2024 restructuring, plus the revision of franchise fee arrangements in April 2025, with both measures geared to enhance long-term sustainability.
- EBITDA of US$70 million, down by 21 per cent YoY, with margins consolidating around the 40 per cent mark.
- Net income of US$51 million, up by 9 per cent YoY, with net income margins expanding from 23 to 29 per cent.
- Operating expenses fell from US$86 million to US$60 million, reflecting a decrease in stock-based compensation costs.
Looking ahead, SBC believes it’s in a good position to foster sustainable top-line growth by strengthening its multiple dermatology brands, further expanding into the non-aesthetic healthcare space, as well as making inroads into strategic international markets.
SBC Medical Group stock (NASDAQ:SBC), recently included in the Russell 3000 Index, has given back more than 40 per cent since inception in 2024, last trading at US$3.18, shunning a robust business with profitable operations capable of self-funding its future in an essential industry.
Stephen Rodgers, Head of Global Planning and Strategy at SBC Medical Group, joined Stockhouse’s Ricki Lee to discuss improvements to English-speaking inbound customer support at the company’s Shonan Beauty Clinic, the largest cosmetic medical clinic in Japan. Watch the interview here.
Delta Gold Technologies
From an essential industry today to one positioned to shape our collective futures, we shift to Delta Gold Technologies, market cap US$146 million, a company developing IP in the quantum computing space, where the principles of quantum mechanics hold the promise of yielding computers that vasty outperform your average laptop, heralding newfound levels of insights spanning science, drug discovery and data analysis more broadly.
Unsurprisingly, quantum computing is expected to create trillions in value over the next decade, with heavy hitters like Google, Microsoft and Amazon well involved. That said, players big and small are dealing with the same problem at the moment, and that’s successfully operating qubits, the fundamental units of quantum information, without the need to cool them to near absolute zero (-459 degrees Fahrenheit) to make sure they can reliably process more information than a classical CPU could ever hope to handle.
This is where Delta Gold Technologies comes in with its ongoing investigations into nano-scale gold’s superconductive properties and their potential to enable scalable qubit development.
The company is funding a three-year, C$3 million research sponsorship agreement with the University of Toronto headed by Professor Harry Ruda, which seeks to build on previous evidence for nano-scale gold’s applications across quantum computing. Delta will maintain a 100 per cent license on the IP, with U of T retaining a 1.5 per cent royalty of any net sales.
Delta Gold is undertaking a similar three-year, US$3 million agreement with Penn State University to expand gold-based quantum technologies and commercialize them under an exclusive license in all fields except human health. Under the agreement, Penn State is entitled to receive a 1 per cent royalty on net sales in excess of US$20 million.
The company’s ultimate goal is to create a global quantum research operation, facilitating collaborations between top researchers and institutions that expedite the pace of new technological developments. In so doing, Delta intends to gain a leg up on harvesting industry value through commercial licenses with parties that could benefit from next-gen data processing speeds, including chip makers, militaries, financial firms and software companies.
With monetization expected as soon as 2027, as per slide 19 of the February 2026 investor deck, and founders highly aligned with retail investors at 32 per cent ownership, the broader market has been quick to support the company’s value proposition, lifting Delta Gold stock (USOTC:DGQTF) by 485 per cent since its US listing in February 2026.
R. Michael Jones, Delta Gold’s CEO, joined Ricki Lee to shed light on the first invention made under the partnership with U of T, triggering the filing of a provisional patent that better equips the company to deliver on long-term profitability. Watch the interview here.
Thanks for reading! I’ll see you next Monday for a new edition of Weekly Market Movers, where I delve into companies that joined Stockhouse for an interview over the past week. Here’s the most recent article, in case you missed it.
Join the discussion: Find out what investors are saying about these attractive small-cap stocks on the SBC Medical Group Holdings Inc. and Delta Gold Technologies PLC Bullboards, and make sure to explore the rest of Stockhouse’s stock forums and message boards.